Abstract
Type-2-diabetes mellitus, behoort samen met hypertensie, centrale obesitas en karakeristieke dyslipidemie tot het ‘insulineresistentiesyndroom’. Al in 1988 beschreef Gerald Reaven dit ‘syndrome-X’ in zijn Banting lecture (1). Later zijn daar diverse andere factoren aan toegevoegd, zoals hypercoagulabiliteit en endotheeldisfunctie.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Referenties
Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.
United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 836–53.
Martens FMAC, Visseren FLJ, Lemay J, Koning EJP de, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62: 1463–80.
Gale EAM. Lessons from the glitazones: a story of drug development. Lancet 2001; 357: 1870–75.
Glaxo Smith Kline. Us prescribing information for Avandia (rosiglitazone maleate tablets). www.gsk.com/avandia. Farmacotherapeutisch kompas.
Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. The Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diab Care 2001; 24: 1226–32.
Buch HN, Baskar V, Barton DM, Kamalakannan D, Akarca C, Singh BM. Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes. Diab Med 2002; 19; 572–76.
Krische D. The glitazones: proceed with caution. West J Med 2000; 173: 54–59.
Henriksen JE, Kjaer Poulsen M, Levin K, Hojlund K, Beck-Nielsen H. Triple therapy using metformin, rosiglitazone and insulin aspart is superior to NPH insulin twice daily in patients with type 2 diabetes mellitus. Diabetologia 2002; 45: Suppl 2-A263.
Dormandy J, Charbonnel B, Eckland D. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) a randomized controlled trial. Lancet 2005; 366: 1279–89.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457–71.
EMEA. http://www.emea.europa.eu/pdfs/human/press/pr/48427707en.pdf
Author information
Authors and Affiliations
Copyright information
© 2010 Bohn Stafleu van Loghum
About this chapter
Cite this chapter
Veneman, T.F. (2010). Welke plaats is er voor combinatietherapie van insuline met thiazolidinedionen bij diabetes mellitus type 2?. In: De meest gestelde vragen over: Diabetes mellitus. De meest gestelde vragen over: diabetes mellitus. Bohn Stafleu van Loghum, Houten. https://doi.org/10.1007/978-90-313-7342-0_11
Download citation
DOI: https://doi.org/10.1007/978-90-313-7342-0_11
Publisher Name: Bohn Stafleu van Loghum, Houten
Print ISBN: 978-90-313-7341-3
Online ISBN: 978-90-313-7342-0
eBook Packages: Dutch language eBook collection